| Document |
Document Title |
|
WO/2023/133399A1 |
Described are methods for treating patients with pulmonary hypertension associated with sarcoidosis (PH-SARC) using inhaled nitric oxide (iNO).
|
|
WO/2023/133217A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/131608A1 |
The present disclosure related to a pharmaceutical formulation comprising particles comprising 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acet
ic acid (selexipag metabolite), or a pharmaceutically acceptable salt, hydrate, s...
|
|
WO/2023/132208A1 |
The present invention addresses the problem of providing a pharmaceutical composition for preventing and/or treating heart failure. The present invention pertains to a pharmaceutical composition or the like that is for preventing and/or ...
|
|
WO/2023/131017A1 |
Disclosed in the present invention are a crystal form of a fused ring derivative, and a preparation method therefor and the use thereof. The crystal form I of the compound as represented by formula (A) of the present invention has high p...
|
|
WO/2023/130541A1 |
Provided in the present invention are a 2-pyrazole-3-benzimidazole derivative, a preparation method therefor and the use thereof, the 2-pyrazole-3-benzimidazole derivative having a structure represented by formula (I). Experimental resul...
|
|
WO/2023/132699A1 |
The present disclosure relates to a sustained-release tablet comprising carvedilol granules in which the carvedilol granules are contained in an amount of 33 to 53 wt% based on the total weight of the tablet, and to a method for preparin...
|
|
WO/2023/133375A1 |
The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as autoimmune disease.
|
|
WO/2023/131349A1 |
A treprostinil coupled nitric oxide (NO) donor drug as shown in formula I below, a pharmaceutical composition thereof and a use thereof.
|
|
WO/2023/125716A1 |
Provided in the present invention are a class of quinoline compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided in the present invention are a compound as shown in formula ...
|
|
WO/2023/124545A1 |
An extraction method for safflower oil and a xinnaoqing soft capsule, belonging to the technical field of medicine preparation. The extraction method comprises: adding a safflower medicinal material and alkaline cellulase into a PBS solu...
|
|
WO/2023/125792A1 |
The present invention relates to a multi-substituted uracil derivative and a preparation method therefor and an application thereof. Specifically, the compound of the present invention has a structure as shown in formula (I) in which the...
|
|
WO/2023/127961A1 |
According to the present invention, provided is a composition for inducing satiety or suppressing overeating. This invention provides a GABA-containing composition for inducing transient satiety in a subject. This invention also provid...
|
|
WO/2023/125708A1 |
Disclosed in the present disclosure are a compound shown in formula (I), a racemate, stereoisomer, tautomer, isotopic label, solvate, pharmaceutically acceptable salt or prodrug thereof, a composition thereof, a preparation method theref...
|
|
WO/2023/123468A1 |
Provided in the present invention are a cardiovascular and cerebrovascular drug and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula (I), wherein each group is defined as desc...
|
|
WO/2023/127012A1 |
Provided is a therapeutic drug that is useful for treating aneurysm. A medicinal composition for treating and/or preventing aneurysm that comprises at least one of the following agents i) to iii) as an active ingredient. i) An agent ...
|
|
WO/2023/128710A1 |
The present invention relates to a tablet containing a mixed extract of Cinnamomi Ramulus and Moutan Radicis Cortex as an active ingredient and provides a method for preparing the tablet. A preferred dosage of the tablet, supported by an...
|
|
WO/2023/129883A1 |
A pharmaceutical premix formulation comprising from about 10 mcg/ml to about 70 mcg/ml epinephrine and a salt is described, wherein the formulation is an aqueous, premix formulation and has a pH from about 2 to about 6. Uses and systems ...
|
|
WO/2023/129377A1 |
This document relates to methods and materials for treating a mammal (e.g., a human) having, or at risk of having, a heart attack (also called a myocardial infarction). For example, one or more inhibitors of a period circadian protein (P...
|
|
WO/2023/125745A1 |
Provided are an anti-βKlotho antibody and the use thereof. The anti-βKlotho antibody can be used for treating βKlotho-mediated or βKlotho-FGFR1c-FGF21-mediated diseases, especially abnormal metabolic diseases, such as type 1 diabetes...
|
|
WO/2023/123008A1 |
The present invention belongs to the field of biological medicine, and specifically relates to a biguanide derivative and the use thereof. The structural formula of the biguanide derivative of the present invention is as represented by f...
|
|
WO/2023/128898A1 |
The present invention relates to the preparation of pharmaceutical compositions comprising macitentan is indicated for the treatment of pulmonary arterial hypertension (PAH), having a specific weight ratio of binder to disintegrant in fo...
|
|
WO/2023/128874A1 |
The disclosure herein relates to engineered nucleic acids, so-called nucleic acid sponges. These engineered nucleic acids comprise a plurality, preferably 2-6, stem-loop structures whereby each loop binds to an individually selected targ...
|
|
WO/2023/125707A1 |
Disclosed in the present disclosure are a compound as shown in formula I, a racemate, a stereoisomer, a tautomer, an isotope label, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a composition thereof, a preparat...
|
|
WO/2023/127853A1 |
Provided is a compound represented by formula (1) or a pharmaceutically acceptable salt thereof (in formula (1), Ar is formula (Ar1) or (Ar2), and in these formulas, R1 and R2 each independently denote an alkyl, a haloalkyl, or a halogen...
|
|
WO/2023/128902A1 |
The present invention relates to the preperation of pharmaceutical compositions comprising bosentan or a pharmaceutically acceptable salt or solvate thereof, and also relevant excipients; in the treatment of pulmonary arterial hypertensi...
|
|
WO/2023/125536A1 |
Provided in the present disclosure is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has a VEGF inhibitory effect, and can be used for preventing and treating diseases or conditions r...
|
|
WO/2023/125719A1 |
Disclosed in the present invention are a Veronica undulata extract as well as a preparation method therefor and the use thereof. The Veronica undulata extract contains iridoid glycoside active ingredients, and the iridoid glycoside activ...
|
|
WO/2023/130028A1 |
This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment o...
|
|
WO/2023/130009A1 |
A sterile, ready-to-use pharmaceutical composition having hydralazine and/or a salt thereof at a concentration of less than about 20 mg/mL and a solvent comprising an organic co-solvent, wherein the hydralazine and/or salt thereof and th...
|
|
WO/2023/125275A1 |
Provided are a salt of an aminopyrimidine compound and a use thereof. Specifically, provided are a salt of (S)-2-(1-((6-amino-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyrimidi
n-4-yl)amino)ethyl)-5-(3-hydroxyprop-1-yn-1-yl)-3-phenylquin
azolin-4...
|
|
WO/2023/127909A1 |
Provided is a therapeutic drug that is useful for treating arterial aneurysm. The pharmaceutical composition for treating and/or preventing arterial aneurysm comprises at least one of the following chemical agents i) to iii) as an acti...
|
|
WO/2023/126026A2 |
The present application relates to an EPA-EE lipid nanocomposite, a formulation thereof, a preparation method therefor, and an application thereof. The EPA-EE lipid nanocomposite has a raw material having a high concentration of EPA-EE a...
|
|
WO/2023/127883A1 |
The present invention provides a compound indicated by general formula (1) and having mPGES-1 inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, R1 and R2 each independently indicate hy...
|
|
WO/2023/123215A1 |
Provided are the uses of extracellular vesicles. Further specifically provided are the uses of extracellular vesicles in the aspects of adjusting the ovarian function, prolonging the life of mammals or preventing aging, treating or preve...
|
|
WO/2023/119063A1 |
Described are the use of placental extract and compositions comprising placenta extract to treat or prevent inflammation of a disease or condition associated with TNFα, IL-1beta, IL-6 and other pro-inflammatory cytokines, such as asthma...
|
|
WO/2023/120552A1 |
The present specification discloses a reduced coenzyme Q10 product which does not require the formulation of reduced coenzyme Q10 and in which the oxidation of reduced coenzyme Q10 is suppressed. Also, the present specification discloses...
|
|
WO/2023/117914A1 |
Cyclopentathiophene carboxamides of formula (I), wherein R1, R2, R3, R4, and n are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can...
|
|
WO/2023/116748A1 |
Provided are a compound as represented by formula (I) and a pharmaceutical composition thereof. The compound or the pharmaceutical composition can regulate the activity of JAK, especially the activity of TYK2, and can be used for prevent...
|
|
WO/2023/118092A1 |
The present invention relates to substituted pyrazolo[l,5-a]pyridine-[3,2-e]pyrimidines compounds of formula (I) wherein X, R1, and R2 are as defined in the claims, methods of preparing said compounds, pharmaceutical compositions and com...
|
|
WO/2023/121689A1 |
Various methods and compositions for treating single ventricle heart disease (SVHD) patients, including patients who have undergone Fontan surgery and who have Fontan circulation (Fontan patient), to improve exercise performance, especia...
|
|
WO/2023/122804A1 |
Provided herein is a recombinant AAV (rAAV) comprising an AAV capsid and a vector genome packaged therein, wherein the vector genome comprises an AAV 5' inverted terminal repeat (ITR), and expression cassette comprising an open reading f...
|
|
WO/2023/120558A1 |
The present specification discloses a method for storing reduced coenzyme Q10 (QH), the method being capable of suppressing oxidation. The first embodiment of the present invention relates to a method for storing QH, the method includi...
|
|
WO/2023/120704A1 |
The present disclosure provides a composition that is for improving a heart function and that contains a compound represented by formula (I), or an ester, oxide, prodrug, pharmaceutically acceptable salt or solvate thereof. Also provided...
|
|
WO/2023/120612A1 |
The purpose of the present invention is to provide a therapeutic or prophylactic agent for heart attack, heart fibrosis, or heart failure, targeted on Htra3. The present invention provides a therapeutic or prophylactic agent for heart at...
|
|
WO/2023/120557A1 |
The present description discloses a packaged body of reduced coenzyme Q10, which eliminates the need for formulating the reduced coenzyme Q10 into a preparation, does not undergo the oxidation of the reduced coenzyme Q10 and can be store...
|
|
WO/2023/122045A1 |
Disclosed herein are methods and compositions for treating dilated cardiomyopathy. In embodiments, the methods and compositions are effective in inhibiting PDGFRA signaling.
|
|
WO/2023/120555A1 |
The present description discloses a favorable means for suppressing oxidation of reduced coenzyme Q10 (QH) without requiring formulation of QH. At least one embodiment of the present invention relates to a method for storing reduced co...
|
|
WO/2023/115628A1 |
The present invention relates to the technical field of medicine. Provided is a composition, comprising the following components: β-nicotinamide mononucleotide, blood orange concentrated powder and astaxanthin. It is found in the study ...
|
|
WO/2023/115149A1 |
This invention relates to compounds of formula (X) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (X) to treat necroptosis, and/or inhibi...
|
